FDA Software Validation: A Practical Compliance Guide

FDA software validation is the process of generating objective evidence that software consistently meets user needs and intended uses, and under 21 CFR Part 820, it is a legal obligation for device manufacturers, not an optional quality exercise. If your software is embedded in a device, functions as a medical device itself, or runs your production line or quality management system, you need a documented validation program before that software touches a regulated process.

Three things you must do right now:

1. Create a validation plan that defines scope, objectives, roles, and the evidence you will generate.
2. Classify your software by intended use and risk using the FDA’s Computer Software Assurance (CSA) framework to determine how deep your assurance activities need to go.
3. Assemble the minimal core evidence set: a software requirements specification (SRS), test protocols with pass/fail criteria, and a traceability matrix linking requirements to tests to results.

The General Principles of Software Validation remains the foundational FDA guidance document for this work, and the newer Computer Software Assurance guidance updates the risk philosophy for production and QMS software. Both belong on your desk before you write a single test case.

Key Takeaways

A risk-based CSA approach, applied honestly at the feature level, produces a stronger and leaner FDA software validation package than exhaustive testing of every function.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Table of Contents

• Which software does the FDA expect you to validate?
• What regulations and guidances govern FDA software validation?
• How does the FDA’s risk-based CSA framework work in practice?
• What validation activities happen across the software lifecycle?
• What testing and objective evidence does the FDA accept?
• How should you manage changes and know when to revalidate?
• What goes into a premarket submission or validation package?
• What does a realistic validation timeline look like?
• Common pitfalls that create compliance risk
• Bitrupt builds FDA-ready software with validation built in from day one
• Sources

Which software does the FDA expect you to validate?

Not every piece of software in your organization needs a full validation package. The FDA draws clear lines, and misclassifying your software is one of the most common and costly mistakes teams make.

The main categories that carry validation obligations are:

• Device-embedded software and firmware — code that runs on or controls a medical device, including firmware in diagnostic instruments, infusion pumps, and imaging systems.
• Software as a Medical Device (SaMD) — standalone software intended to diagnose, treat, cure, or prevent disease, including cloud-hosted clinical decision support tools.
• Production and manufacturing software — MES platforms, automated inspection systems, and robotics controllers used on the manufacturing floor.
• Quality management system automation — LIMS, document control systems, CAPA tracking tools, and any platform that stores or processes quality records.
• Computerized systems for electronic records and electronic signatures — any system subject to 21 CFR Part 11 where records must be trustworthy, reliable, and equivalent to paper records.

Concrete examples help here. A cloud-based MES that logs batch records requires validation. A LIMS that stores certificate-of-analysis data requires validation. An off-the-shelf statistical tool used to generate device design outputs requires validation. A general-purpose spreadsheet used only for internal scheduling, with no quality record output, typically does not.

Pro Tip: Ask two questions about any software: Does it produce or modify a quality record? Does its failure mode directly affect device safety or product quality? If either answer is yes, validate it. If both answers are no, document your rationale for exclusion and move on.

For SaaS tools and cloud deployments, the FDA recognizes that IaaS, PaaS, and SaaS models can all fall within validation obligations. Documenting the intended use is the first step in deciding whether validation applies, as the CSA guidance makes clear.

What regulations and guidances govern FDA software validation?

Think of this as your regulatory map. You do not need to memorize every word of every document, but you do need to know which ones apply to your situation and what each one demands.

IEC 62304 and ISO 13485 are not legally required by the FDA, but aligning to them is effectively the industry benchmark. According to MedDeviceGuide, following IEC 62304 produces a large portion of the documentation FDA reviewers expect. Deviating from it means you must demonstrate an equivalent level of rigor through other means — a harder argument to make during an inspection.

How does the FDA’s risk-based CSA framework work in practice?

The CSA guidance represents a genuine shift in how the FDA wants you to think about validation. The old model pushed teams toward exhaustive testing of every feature. CSA replaces that with a simpler question: how much does this software’s failure risk harming device safety or product quality? Your assurance effort scales to that answer.

Here is how to apply it:

• Identify intended use at the feature level. A single platform might have features that directly affect batch release decisions (high risk) and features that only generate internal reports (low risk). Treat them differently.
• Map each feature or function to a role: production/QMS impact vs. support-only. Features with direct impact on safety or quality get deeper testing and more formal documentation. Support-only features may need only basic functional checks.
• Classify risk. High-risk features (those whose failure could cause a product defect or patient harm) warrant formal test protocols, independent review, and detailed objective evidence. Lower-risk features can use lighter-weight approaches like sampling or exploratory testing.
• Document your rationale. This is the part most teams skip, and it is exactly what auditors look for. Write down why you assigned a given risk level, what evidence you generated, and why that evidence is sufficient.

Pro Tip: Create a one-page risk classification table at the start of every validation project. List each software function, its intended use, its risk tier (high/medium/low), and the assurance approach you chose. An auditor who sees this table immediately understands your logic — and that transparency is worth more than a hundred pages of undifferentiated test scripts.

The CSA framework also applies to COTS and SaaS tools. You cannot validate the vendor’s source code, but you can validate that the tool performs its intended function in your specific environment. Document the intended use, test the functions you rely on, and keep records of the vendor’s own quality documentation.

What validation activities happen across the software lifecycle?

Validation is not a final step. Evidence should be generated iteratively across every phase of development, from planning through retirement. Think of it like building a house: the inspection at the end only passes because the foundation, framing, and electrical were each checked as they went in.

Here is the phase-by-phase sequence:

1. Validation planning — Define scope, objectives, roles, risk classification, and the evidence package. Output: Validation Plan.
2. Software requirements specification (SRS) — Document what the software must do, including functional, performance, security, and interface requirements. Output: SRS document.
3. Design controls — Under 21 CFR Part 820, design inputs must be traceable to design outputs. For software, this means architecture documents, interface specifications, and design reviews. Output: Design History File (DHF) entries.
4. Unit and integration verification — Confirm that individual modules and their interactions perform as specified. Output: Unit test reports, integration test reports.
5. System-level validation testing — Confirm the complete system meets user needs and intended use in a representative environment. Output: System test protocols and reports.
6. Traceability matrix — Link every requirement to at least one test case and at least one test result. Output: Requirements Traceability Matrix (RTM).
7. Release criteria review — Confirm all planned tests passed, all deviations are resolved or risk-accepted, and the evidence package is complete. Output: Validation Summary Report.
8. Configuration management and retirement — Maintain version control throughout; document decommissioning when the software is retired.

Verification vs. validation is a distinction worth getting right. Verification asks: are we building the product correctly? It checks design outputs against design inputs at each development stage. Validation asks: is this the right product for the intended use? It confirms the finished system meets user needs in practice. Both are required; neither substitutes for the other.

A traceability matrix does not need to be elaborate. At minimum, each row should capture: requirement ID, requirement description, test case ID, test result (pass/fail), and a reference to the test report. Keep it live throughout development rather than reconstructing it at the end.

What testing and objective evidence does the FDA accept?

The FDA does not prescribe a single testing methodology. What it requires is objective evidence — documented proof that the software performs as intended under conditions representative of actual use.

Accepted testing approaches include:

• Unit tests — automated or manual tests of individual functions or modules against their specifications.
• Integration tests — tests of interfaces and data flows between components or between the software and external systems.
• System tests — end-to-end tests of the complete system against user requirements in a representative environment.
• Acceptance tests — formal tests confirming the system meets acceptance criteria defined in the validation plan.
• Automated regression tests — repeatable test suites that confirm existing functionality is not broken by changes; particularly valuable for ongoing maintenance.
• Exploratory testing — structured, unscripted testing to identify unexpected behaviors, especially useful for complex workflows.
• Equivalence and boundary testing — for COTS or SOUP components, testing that confirms the component behaves correctly within the specific parameters your system uses.

Objective evidence means more than a list of test names. Each artifact should include: a test protocol with defined pass/fail criteria written before execution, execution logs showing actual results, the environment configuration (hardware, OS, software versions, data sets), and a signed test report with the tester’s identity and date. Screenshots, SBOMs listing third-party components, and configuration records all strengthen the package.

Test environment representativeness is a point FDA reviewers scrutinize closely. Your test system should mirror the intended production environment in configuration, data volume, and interface connections. A test run on a developer’s laptop against a synthetic dataset does not demonstrate that the system performs correctly in a cloud-hosted production environment with real data loads.

How should you manage changes and know when to revalidate?

Change control is where many otherwise solid validation programs fall apart. A validated system stays validated only as long as changes are assessed, documented, and tested before deployment.

A defensible change-control process follows these steps:

1. Log the change request with a description of what is changing and why.
2. Perform an impact analysis — identify which requirements, functions, and validated states the change could affect.
3. Re-assess risk — does the change alter the software’s intended use, introduce new failure modes, or affect a high-risk function?
4. Define regression testing scope — test the changed function plus any dependent functions identified in the impact analysis.
5. Update the traceability matrix to reflect new or modified requirements and their test coverage.
6. Obtain approval from QA and, where required, regulatory affairs before deployment.

Common triggers that require revalidation include: changes to intended use or clinical claims, modifications to critical algorithms (dosing calculations, diagnostic logic), updates to production automation that affect batch release, and replacement of SOUP or COTS components that the validation relied on.

Minor bug fixes with no impact on validated functions can often be handled with a lighter-weight change assessment and targeted regression testing. The key is documenting the rationale. A one-paragraph impact analysis that concludes “no effect on validated functions” is defensible if the reasoning is sound. Deploying a fix with no documentation at all is not.

What goes into a premarket submission or validation package?

Whether you are preparing a 510(k), a PMA, or an internal Design History File, the validation portion of your submission package should give reviewers a clear, navigable picture of how the software was developed, tested, and controlled.

The FDA’s premarket submissions guidance recommends a least-burdensome approach: include the minimum information needed for review, organized so reviewers can find it without hunting.

Your submission package should include:

• Validation plan — scope, risk classification, methodology, and acceptance criteria.
• Software requirements specification — functional, performance, interface, and security requirements.
• Risk analysis — linked to ISO 14971; identifies hazards, failure modes, and mitigations.
• Test protocols and reports — with pass/fail criteria, execution records, and tester sign-offs.
• Traceability matrix — requirements to tests to results, with no gaps.
• SBOM and cybersecurity evidence — list of third-party components, known vulnerabilities, and mitigations.
• Change history and problem reports — a record of issues found during development and how they were resolved.
• IEC 62304 and ISO 13485 alignment evidence — where applicable, a cross-reference showing how your lifecycle processes map to these standards.

Add a one-page executive summary at the front that states the software’s intended use, safety class, and a brief description of the validation approach. Then provide a navigation map pointing reviewers to each artifact in the DHF. This small investment in organization saves significant back-and-forth with the review division.

For founders and early-stage teams navigating the broader regulatory picture, a practical primer on healthcare startup regulatory basics can help frame where software validation fits within the full FDA submission process.

What does a realistic validation timeline look like?

Planning a validation program without a timeline is like starting construction without a schedule. Here is a realistic phase map for a regulated software project, with deliverables at each stage.

1. Discovery and classification (2–4 weeks) — Confirm intended use, perform risk classification, identify applicable regulations and guidances, and draft the validation plan. Deliverables: Validation Plan, risk classification table.
2. SRS and design controls (2–4 weeks) — Write the software requirements specification, establish design inputs and outputs, and set up the traceability matrix. Deliverables: SRS, initial RTM, design review records.
3. Incremental verification and integrated validation (6–12 weeks) — Execute unit, integration, and system tests iteratively; update the RTM with results; manage SOUP and COTS components. Deliverables: Test protocols, test reports, updated RTM, SBOM.
4. Pre-release validation and submission prep (2–6 weeks) — Execute acceptance tests, resolve open defects, complete the validation summary report, and assemble the submission package. Deliverables: Validation Summary Report, change-control log, final submission package.

When engaging a vendor partner, ask specifically: Do your engineers have prior experience with FDA-regulated projects? Can you provide sample validation artifacts from past engagements? How do your project milestones align to design control gates? What is your process for maintaining the traceability matrix during development?

Pro Tip: Align vendor milestones directly to your design control gates in the quality system. When a vendor’s sprint review coincides with a design review checkpoint, the evidence generated in that sprint feeds directly into the DHF — no reconstruction required at the end. This is the single biggest time-saver in regulated software projects.

Bitrupt’s healthcare software development practice builds this alignment into every engagement, with senior engineers who understand both the technical and regulatory dimensions of FDA-ready platforms.

Common pitfalls that create compliance risk

Most validation failures are predictable. Here is what to avoid, and what to do instead.

Do not do these:

• Delay documentation until the end. Reconstructing a traceability matrix from memory after development is complete produces weak evidence that reviewers can pick apart easily.
• Misclassify intended use. Calling a production-critical function a “support tool” to avoid validation work is a compliance risk that surfaces during inspections.
• Treat every feature equally. Applying the same documentation depth to a low-risk reporting feature as to a high-risk dosing algorithm wastes resources and obscures your risk logic.
• Ignore SOUP and SBOM requirements. Third-party libraries and open-source components are part of your validated system. If you cannot account for them, neither can a reviewer.

Do these instead:

• Integrate risk management with design controls from day one, not as a separate parallel track.
• Keep the traceability matrix live throughout development; assign one person to own it.
• Automate repeatable regression tests so change-control testing does not become a bottleneck.
• Involve QA and regulatory affairs at the requirements stage, not after the first build.
• Plan change-control procedures before the first release, not after the first change request arrives.

Weak evidence that commonly draws inspection questions includes: test reports with no defined pass/fail criteria, traceability matrices with requirements that map to zero test cases, and validation summaries that describe the testing approach without showing actual results. Reviewers are not looking for perfection; they are looking for a coherent, documented rationale.

What experienced teams know about FDA software validation that most guides miss

Most articles on this topic treat FDA software validation as a documentation exercise. That framing leads teams to produce paperwork that satisfies the form of compliance without the substance of it.

The CSA framework is a genuine improvement over the old exhaustive-testing model, but only if you apply it honestly. The risk classification step is where the real intellectual work happens. A team that spends two days thinking carefully about intended use and failure modes before writing a single test case will produce a stronger validation package than a team that spends two weeks writing test scripts without that foundation.

There is also a practical argument for getting this right early: rework in a regulated project is expensive in ways that go beyond engineering hours. A validation package that needs to be rebuilt after a 510(k) submission delays market entry, and a failed inspection during manufacturing can trigger a warning letter. The cost of doing it right the first time is almost always lower than the cost of fixing it under pressure.

For teams building SaMD or SaaS tools used in clinical workflows, developing a rigorous clinical use case early in the process is one of the most effective ways to anchor the intended use documentation that validation depends on.

The teams that handle this best share one trait: they treat the validation program as a product artifact, not a compliance tax. The traceability matrix is a living engineering document. The test reports are quality evidence, not bureaucratic paperwork. When that mindset takes hold, the documentation gets better and the compliance burden actually decreases.

Bitrupt builds FDA-ready software with validation built in from day one

Regulated software projects fail not because teams lack technical skill, but because validation is treated as an afterthought. Bitrupt’s FDA-ready healthcare engineering practice embeds validation planning, traceability, and QA into every sprint from the start, so the evidence package builds itself as development progresses. Every engagement is staffed with senior engineers who have worked on regulated platforms, and deliverables include validation plans, SRS documents, RTMs, SBOM assembly, and test automation built to inspection standards.

If you are evaluating a regulated-software partner, ask them: Can you show a sample traceability matrix from a prior engagement? How do your sprint milestones map to design control gates? What is your process for managing SOUP components and change control? Bitrupt answers all three with documented examples.

Ready to scope your validation program? Start a discovery conversation with Bitrupt’s engineering team and get a clear picture of your validation roadmap within one week.

Sources

• General Principles of Software Validation | FDA
• Computer Software Assurance for Production and Quality Management System Software (PDF)
• 21 CFR Part 820 — Quality System Regulation
• Content of Premarket Submissions for Device Software Functions — Federal Register notice

Recommended

• GDPR Compliance Workshop — 1–2 weeks, Remote | Bitrupt | Bitrupt
• FHIR API Integration: A Practical Playbook for Healthcare IT | Bitrupt
• Software & AI Engineering in Dover, Delaware — Bitrupt | Bitrupt
• Quality Engineering — Automated Testing, E2E & Release Gates | Bitrupt